Abstract
Two biopesticide firms last week settled out of court a pair of lawsuits over potentially lucrative patent rights on Bacillus thuringiensis (Bt). Bt is a naturally occurring bacterium that produces toxins against insects, and is the basis of the budding biopesticide industry. The worldwide market for Btbased pesticides is projected to grow at an annual rate of 20%, from $60 million in 1991 to $115 rnillion by 1995. The lawsuits were filed in 1988 in the U.S. District Court in Southern California by Novo Nordisk of Denmark. Novo Nordisk charged that Mycogen, a San Diego-based agricultural biotechnology company, infringed on and interfered with Novo Nordisk patents for Bt strains active against Coleoptera, or beetles. The patents are now assigned to Entotech, a Davis, Calif.-based biopesticide R&D unit of Novo Nordisk. As part of the settlement, Mycogen formally acknowledges that the Bt strain it named B. thuringiensis subsp. san diego is identical to the Bt strain ...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
